Get the Stockscreener App
4.91
1.60%
-0.08
After Hours:
4.91
Compass Therapeutics Inc stock is traded at $4.91, with a volume of 2.39M.
It is down -1.60% in the last 24 hours and down -11.21% over the past month.
Compass Therapeutics Inc is a clinical-stage biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat solid tumors and hematological malignancies. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to drug the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-IO Bispecific, and CTX-8371.
See More
Previous Close:
$4.99
Open:
$4.91
24h Volume:
2.39M
Relative Volume:
1.22
Market Cap:
$873.30M
Revenue:
-
Net Income/Loss:
$-45.44M
P/E Ratio:
-14.03
EPS:
-0.35
Net Cash Flow:
$-42.28M
1W Performance:
-8.74%
1M Performance:
-11.21%
6M Performance:
+76.62%
1Y Performance:
+210.76%
1-Day Range:
$4.79
$5.05
1-Week Range:
$4.79
$5.45
52-Week Range:
$1.33
$5.86
Compass Therapeutics Inc Stock (CMPX) Company Profile
Name
Compass Therapeutics Inc
Sector
Industry
Phone
617-500-8099
Address
80 GUEST STREET, BOSTON
Compare CMPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CMPX
Compass Therapeutics Inc
|
4.91 | 887.53M | 0 | -45.44M | -42.28M | -0.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.38 | 113.87B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.54 | 80.22B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
406.40 | 52.56B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
803.74 | 49.31B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.07 | 37.37B | 447.02M | -1.18B | -906.14M | -6.1812 |
Compass Therapeutics Inc Stock (CMPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-05-26 | Initiated | William Blair | Outperform |
| Dec-03-25 | Initiated | Canaccord Genuity | Buy |
| Dec-03-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-03-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-01-25 | Resumed | Raymond James | Outperform |
| Apr-02-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Feb-24-25 | Initiated | Guggenheim | Buy |
| Feb-19-25 | Initiated | Piper Sandler | Overweight |
| Dec-23-24 | Initiated | D. Boral Capital | Buy |
| Nov-15-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-16-24 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-31-23 | Initiated | Jefferies | Buy |
| Jan-27-23 | Initiated | Stifel | Buy |
| May-23-22 | Resumed | H.C. Wainwright | Buy |
| Mar-15-22 | Initiated | Ladenburg Thalmann | Buy |
| Jan-19-22 | Initiated | B. Riley Securities | Buy |
| Dec-22-21 | Initiated | Raymond James | Outperform |
| Dec-20-21 | Initiated | SVB Leerink | Outperform |
| Dec-15-21 | Initiated | Wedbush | Outperform |
View All
Compass Therapeutics Inc Stock (CMPX) Latest News
Stifel reiterates Buy rating on Compass Therapeutics stock with $12 target - Investing.com UK
Raymond James reiterates Outperform rating on Compass Therapeutics stock By Investing.com - Investing.com UK
Compass Therapeutics' (CMPX) "Buy" Rating Reaffirmed at D. Boral Capital - MarketBeat
Compass Therapeutics details cash runway and pipeline progress - TipRanks
Compass Therapeutics reports progress across cancer drug pipeline By Investing.com - Investing.com India
Compass Therapeutics Provides Corporate Update - Yahoo Finance
Compass Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Compass Therapeutics, Inc. Announces Executive Appointments, Effective as of January 1, 2026 - marketscreener.com
William Blair Initiates Coverage of Compass Therapeutics (CMPX) with Outperform Recommendation - Nasdaq
Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care - One News Page
Compass Therapeutics announces key leadership appointments - marketscreener.com
Compass Therapeutics appoints new chief commercial and medical officers - Investing.com
Compass Therapeutics Announces Key Leadership Appointments - The Manila Times
New leaders join Compass Therapeutics as it advances cancer drugs - Stock Titan
William Blair initiates coverage on Compass Therapeutics stock with Outperform rating - Investing.com Canada
Which Way Will The Needle Swing For Compass Therapeutics' Biliary Tract Cancer Study? - RTTNews
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5% – What’s Next? - Defense World
Compass Therapeutics (NASDAQ:CMPX) Shares Up 4.5%What's Next? - MarketBeat
Compass Therapeutics files for up to $400 million mixed shelf offeringSEC filing - marketscreener.com
Compass Therapeutics Files $400 Million Mixed Shelf - marketscreener.com
Compass Therapeutics’ (CMPX) Tovecimig Drives Strong Analyst Sentiment - Insider Monkey
Compass Therapeutics' (CMPX) Tovecimig Drives Strong Analyst Sentiment - Finviz
Published on: 2025-12-21 11:19:43 - moha.gov.vn
Compass Therapeutics Earnings Notes - Trefis
Are Medical Stocks Lagging Compass Therapeutics, Inc. (CMPX) This Year? - Yahoo Finance
Is Compass Therapeutics Inc. stock a defensive play in 2025Weekly Loss Report & Technical Confirmation Alerts - DonanımHaber
How Compass Therapeutics Inc. stock reacts to global recession fearsQuarterly Earnings Summary & Community Verified Swing Trade Signals - DonanımHaber
Why Compass Therapeutics Inc. stock could outperform in 2025July 2025 Technicals & Fast Gain Swing Alerts - DonanımHaber
12 Best Multibagger Stocks to Buy Heading into 2026 - Insider Monkey
Patterns Watch: How Compass Therapeutics Inc. stock reacts to global recession fearsPrice Action & Low Risk Profit Maximizing Plans - DonanımHaber
Why analysts remain bullish on Compass Therapeutics Inc. stockJuly 2025 Reactions & Precise Buy Zone Tips - Улправда
How Compass Therapeutics Inc. stock trades during market volatilityWeekly Stock Recap & Comprehensive Market Scan Reports - Улправда
Signal Recap: Is Compass Therapeutics Inc. stock in correction or buying zone2025 Earnings Impact & Low Drawdown Investment Ideas - ulpravda.ru
Published on: 2025-12-19 03:17:09 - Улправда
Published on: 2025-12-19 02:57:37 - Улправда
Compass Therapeutics to Participate in the J.P. Morgan 2026 Healthcare Conference - Yahoo Finance
Wall Street analysts think Compass Therapeutics, Inc. (CMPX) could surge 134.14%: Read this before placing a bet - MSN
Here's why Compass Therapeutics, Inc. (CMPX) is a great momentum stock to buy - MSN
Wall Street Analysts Think Compass Therapeutics, Inc. (CMPX) Could Surge 134.14%: Read This Before Placing a Bet - Zacks Investment Research
An analyst sees good growth prospects for Compass Therapeutics Inc (CMPX) - Setenews
Vivo Capital LLC Purchases 2,487,443 Shares of Compass Therapeutics, Inc. $CMPX - MarketBeat
Here's Why Compass Therapeutics, Inc. (CMPX) is a Great Momentum Stock to Buy - sharewise.com
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Consensus Rating of “Moderate Buy” from Analysts - Defense World
Compass Therapeutics announces public offering of common stock By Investing.com - Investing.com Nigeria
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated at Citizens Jmp - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Now Covered by Analysts at Canaccord Genuity Group - MarketBeat
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Citizens Jmp - Defense World
Analysts Are Bullish on These Healthcare Stocks: Schrodinger (SDGR), Compass Therapeutics (CMPX) - The Globe and Mail
Compass Therapeutics (NASDAQ:CMPX) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Compass Therapeutics Inc Stock (CMPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Compass Therapeutics Inc Stock (CMPX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| GORDON CARL L | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
| ORBIMED ADVISORS LLC | Director |
Apr 09 '25 |
Sale |
1.59 |
3,571,428 |
5,678,571 |
0 |
2.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):